Pulse Steroid Injection in Refractory Rheumatoid Arthritis
NCT ID: NCT06456489
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
268 participants
INTERVENTIONAL
2024-05-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06417398
Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital
NCT04756492
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793
Ultrasound-Based Detection Of Subclinical Arthritis Among Patients With Systemic Lupus
NCT05844917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pulse steroid solumedrol
125 mg of methylprednisolone IV pulse will be administered for two consecutive days followed by oral steroid for 2 weeks with gradual withdrawal.
Solumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days
without pulse
patients will not receive any additional treatment
Solumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Endocrine diseases such as DM and thyroid disorders
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mahrous
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Azhar Univrsity
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Al-Azhar Universiy
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Al-Azhar University
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.